Get started
Author

Aviva G. Asnis-Alibozek

Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer
2008 · Ann H. Partridge, Andrea LaFountain, et al. · Journal of Clinical Oncology · 492
A Review of Contemporary Data on Surgically Resected Renal Masses—Benign or Malignant?
2013 · Anthony T. Corcoran, Paul Russo, et al. · Urology · 81
The unmet need for rapid epileptic seizure termination (REST)
2020 · Aviva Asnis-Alibozek, Kamil Detyniecki · Epilepsy & Behavior Reports · 32
PDF
Incidence of benign versus malignant renal tumors in selected studies.
2012 · Paul Russo, Robert G. Uzzo, et al. · Journal of Clinical Oncology · 12
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial
2024 · Kathryn E Beckermann, Aviva G Asnis-Alibozek, et al. · The Oncologist · 10
PDF
Cost of care for malignant and benign renal masses.
2013 · Aviva G Asnis-Alibozek, Michael J Fine, et al. · PubMed · 10
RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-N,N-diisopropyltryptamine
2024 · Nathan Bryson, Robert Alexander, et al. · ACS Chemical Neuroscience · 9
Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial
2023 · Pedro C Barata, Alexander Chehrazi-Raffle, et al. · The Oncologist · 6
PDF
Long-term PFS from TIVO-3: Tivozanib (TIVO) versus sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC.
2022 · Michael B. Atkins, Elena Verzoni, et al. · Journal of Clinical Oncology · 4
Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients
2024 · Jeffrey Thomas Yorio, Aviva G. Asnis-Alibozek, et al. · BMC Health Services Research · 1
PDF
Estimated cost of adverse event (AE) management for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with a VEGFR TKI.
2023 · Jeffrey Thomas Yorio, Aviva G. Asnis-Alibozek, et al. · Journal of Clinical Oncology
Activity of tivozanib in non-clear cell renal cell carcinoma (nccRCC): Subgroup analysis from a phase 2 randomized discontinuation trial.
2022 · Pedro C. Barata, Kim Allman, et al. · Journal of Clinical Oncology
The Unmet Need for Rapid Epileptic Seizure Termination (REST) Therapy
2021 · Aviva Asnis-Alibozek · Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)
Increasing physician recognition and management of immune-mediated adverse events (imAEs): Results of a structured learning platform.
2018 · Zeshaan Rasheed, Caius Kim, et al. · Journal of Clinical Oncology
Current awareness and use of bevacizumab in advanced cervical cancer: A survey among US community oncologists
2017 · H.J. Dalton, A. Asnis-Alibozek, et al. · Gynecologic Oncology
The Use of An Online Case Database to Obtain Clinical and Psychosocial Information Related to the Selection of and Experience with Initial Systemic Therapy for Multiple Myeloma.
2009 · Neil Love, Sagar Lonial, et al. · Blood
Works count: 16
Citation count: 657
H-index: 7
I10-index: 6
Year
Topic
Type